PURPOSE: To determine failure patterns and survival outcomes of T4N0-1 @entity1149 ( @entity1149 ) treated with definitive radiotherapy. MATERIALS AND METHODS: Ninety-five @entity1 with T4N0-1 @entity1149 who received definitive radiotherapy with or without chemotherapy from May 2003 to October 2014 were retrospectively reviewed. The standard radiotherapy scheme was 66 Gy in 30 fractions. The main concurrent chemotherapy regimen was 50 mg/m(2) weekly @entity1311 combined with 20 mg/m(2) @entity900 or AUC 2 @entity3003 . The primary outcome was @entity1349 ( @entity1349 ). Secondary outcomes were failure patterns and @entity137 . RESULTS: The median age was 64 years (range, 34 to 90 years). Eighty-eight percent of @entity1 (n = 84) had an Eastern Cooperative Oncology Group performance status of 0-1, and 42% (n = 40) experienced pretreatment @entity353 . Sixty percent of @entity1 (n = 57) had no metastatic regional lymph nodes. The median radiation dose was EQD2 67.1 Gy (range, 56.9 to 83.3 Gy). Seventy-one @entity1 (75%) were treated with concurrent chemotherapy; of these, 13 were also administered neoadjuvant chemotherapy. At a median follow-up of 21 months (range, 1 to 102 months), 3-year @entity1349 was 44%. The 3-year cumulative incidences of local recurrence and distant recurrence were 48.8% and 36.3%, respectively. Pretreatment @entity353 and combined chemotherapy were significant factors for @entity1349 . @entity697 over grade 3 occurred in three @entity1 and grade 3 chronic @entity2910 occurred in one @entity1 . There was no grade 3-4 radiation @entity55 . CONCLUSION: Definitive radiotherapy for T4N0-1 @entity1149 results in favorable survival with acceptable @entity137 rates. Local recurrence is the major recurrence pattern. Intensity modulated radiotherapy and radio-sensitizing agents would be needed to improve @entity5 control.

Definitive radiotherapy with or without chemotherapy for clinical stage T4N0-1 XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity697 :: ('MESH:D000208', 'Disease') :: ['Acute esophagitis'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['local tumor'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
